On August 15th, Shandong Jincheng Pharm Group Co., Ltd. (Stock code: 300233) released an announcement regarding the company's actual controller receiving a notice of filing from the China Securities Regulatory Commission.
According to the announcement, on August 14, 2024, Zhao Yeqing, the actual controller and chairman of Shandong Jincheng Pharm Group Co., Ltd. ("Jincheng Pharm"), received a "Notice of Case Filing" from the China Securities Regulatory Commission (referred to as the "CSRC"). The CSRC has initiated an investigation into Zhao Yeqing for suspected illegal activities of market manipulation under the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China.
The company emphasized that this investigation is targeting the personal behavior of Zhao Yeqing, and that the current production and operation of the company is normal. They also stated that they will continue to monitor the progress of the situation and strictly fulfill their obligation to disclose information.
The announcement is as follows:
According to reports, in 2022, Jincheng Pharm announced that its wholly-owned subsidiary, Shandong Jincheng Pharm Chemical Co., Ltd., has received a tobacco monopoly license permit decision letter issued by the State Tobacco Monopoly Administration. This is the first e-cigarette monopoly license permit issued in China.
Currently, Jincheng Pharm has a nicotine production capacity of 200 tons per year and is in the process of upgrading the production line for nicotine extraction, which is soon to be completed and put into use. The company recently stated on an investor communication platform that their newly planned "plant-based nicotine extraction expansion project" has been filed for approval. The project is set to be conducted in two phases, with the first phase focusing on the construction of a 300 tons per year nicotine extraction facility, and the second phase focusing on the construction of a 3000 tons per year fragrance and flavoring facility for use in tobacco products.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
